Article Text

PDF
Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?
  1. Masahiro Mori,
  2. Satoshi Kuwabara
  1. Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
  1. Correspondence to Dr Masahiro Mori, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; morim{at}faculty.chiba-u.jp

Statistics from Altmetric.com

Fingolimod is a sphingosine 1-phosphate (S1P) receptor agonist; it was the first oral disease-modifying agent approved for the treatment of multiple sclerosis (MS). Two double-blind randomised clinical trials (TRANSFORMS and FREEDOMS studies) have shown that in comparison with interferon β-1a or placebo, fingolimod is superior in improving clinical and MRI outcomes in relapsing-remitting MS (RRMS) patients.1 ,2 The FREEDOMS study demonstrated that 0.5-mg fingolimod reduced the annualised relapse rate of RRMS by 55% relative to placebo. On this basis, fingolimod was approved for RRMS treatment in the USA, EU and other countries. To date, more than 77 000 patients have been treated with fingolimod.

In spite of its effectiveness and oral-availability, fingolimod is usually considered as second-line treatment, because it may cause some serious adverse events, particularly cardiovascular related. The European Medicines Agency reported an MS patient who died within 24 h of administration of the first dose of fingolimod. Furthermore, the agency reported …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles